Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Sailpoint | History Defined

SailPoint Q1 Earnings Call Highlights

SailPoint (NASDAQ:SAIL) reported a stronger-than-expected start to fiscal 2027, with management pointing to continued SaaS migration activity, larger customer commitments and growing demand for identity security tied to artificial intelligence agents and other non-human identities. On the company’s

SailPoint Stock’s Big Rally Could Be the Start of a Nice Comeback as Identity Security Takes Center Stage

SailPoint Stock’s Big Rally Could Be the Start of a Nice Comeback as Identity Security Takes Center Stage

SailPoint (SAIL) shares surged more than 11% on Thursday, but that still leaves the stock 50% below its March 2025 high. The stock currently maintains a “Strong Buy” consensus among analysts. While Cerebras Systems (CBRS) dominated headlines with a massive 64% IPO-day pop, SailPoint’s steady progress toward a $1.1 billion...

'Organizations need to stop workarounds and regain control': Report finds many firms don't know what their workers are sharing with AI tools

'Organizations need to stop workarounds and regain control': Report finds many firms don't know what their workers are sharing with AI tools

Workers are using unapproved AI, while AI agents amplify visibility issues by accessing and sharing the wrong data.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Three Stocks Under $20 With Massive Upside Potential

Discover three stocks under $20 with strong analyst support and potential upside of 70% or more for risk-tolerant investors in 2026

UK businesses are putting themselves at risk due to poor cyber hygiene

Employee accounts are a breeding ground for attacks, with poor management, broad permissions, and more.

SailPoint Had a Week to Forget—Is This the Buying Window?

SailPoint’s sharp weekly drop looks mostly market-driven. with strong growth and analyst support, the dip offers an attractive entry point heading into 2026.

Should You Buy the Dip in This Cybersecurity Stock in September 2025?

After its high-profile IPO and a post-earnings dip, SailPoint still boasts robust 33% revenue growth, expanding strategic partnerships, and a “Moderate Buy” analyst consensus—with Wall Street projecting a 24% upside as demand for identity security soars.

inkl

Read news from The Economist, FT, and more,
with one subscription

SailPoint Raises Outlook As CEO Says Identity Security Key For Enterprises, Stock Tumbles

SailPoint Raises Outlook As CEO Says Identity Security Key For Enterprises, Stock Tumbles

SailPoint (NASDAQ:SAIL) stock slid on Tuesday after it reported fiscal second-quarter results.

Top Wall Street Forecasters Revamp SailPoint Expectations Ahead Of Q2 Earnings

Top Wall Street Forecasters Revamp SailPoint Expectations Ahead Of Q2 Earnings

SailPoint, Inc. (NASDAQ:SAIL) will release earnings results for the second quarter before the opening bell on Tuesday, Sept. 9.

Why SailPoint May Cruise Past Cybersecurity Rivals in 2025

Why SailPoint May Cruise Past Cybersecurity Rivals in 2025

SailPoint is building excitement with a distinguished product offering, strong earnings performance, and big partnerships.

Love and hate: tech pros overwhelmingly like AI agents but view them as a growing security risk

Love and hate: tech pros overwhelmingly like AI agents but view them as a growing security risk

Poor oversight, missing policies, and alarming behavior are triggering urgent calls for better identity-based security.

How to protect your business in the age of deepfakes

How to protect your business in the age of deepfakes

The dangers and risks deepfake technology poses to businesses.

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Merger Arbitrage Mondays – Bristol Myers (BMY) Acquires Third Point Therapeutics (TPTX)

Another week and another deal with big pharma buying out a development stage oncology company. Given the real synergies to be had through young companies partnering with big pharma to leverage their manufacturing expertise and distribution networks, regulators have allowed most of them to go through and they tend to…

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bristol Myers Squibb

Cerebras Systems

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

390,743 stories

142,682 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play